Since April 13, 2020, the company has put into operation and operation a medical device for in vitro diagnostics - DIA®-SARS-CoV-2-NP-IgG An enzyme-linked immunosorbent assay for the detection of IgG to the nucleocapsid antigen of SARS-CoV-2 coronavirus.
The test system is intended for the qualitative detection of IgG antibodies to the nucleocapsid antigen of coronavirus SARS-CoV-2 in serum and human blood samples by enzyme-linked immunosorbent assay using standard open-label ELISA equipment.
The test systems are available in various variants of the complete set for carrying out 96, 192 or 480 researches. As part of the test systems, the TMB is ready to use a substrate that does not require preliminary preparation, which reduces the number of technological operations during the production of ELISA.
For delivery, please contact tel. +38 (067) 343-59-83, +38 (044) 463-06-03, send an order: fax +38 (044) 463-06-02 or e-mail: tech@diapr.kiev.ua
Comentários